Imatinib Mesylate (Standard)
Based on 1 Customer Validation
Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.98%
- No. CAS: 220127-57-1
- Fòrmula: C30H35N7O4S
- Peso molecular:589.71
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureza y Documentación
-
Help & FAQs
-
HY-50946
Imatinib Mesylatec-Kit Inhibitor -
HY-15463
ImatinibTyrosine Kinases Inhibitor -
HY-10181
DasatinibSrc/Bcr-Abl Inhibitor -
HY-90006
5-FluorouracilThymidylate Synthase Inhibitor -
HY-15463R
Imatinib (Standard)Tyrosine Kinases Inhibitor -
HY-10159
NilotinibBcr-Abl Inhibitor -
HY-10255A
SunitinibMulti-targeted RTK Inhibitor -
HY-12047
PonatinibMulti-targeted Kinase Inhibitor -
HY-10208
PazopanibVEGFR Inhibitor -
HY-10255
Sunitinib MalateTyrosine Kinase Inhibitor -
HY-10158
BosutinibSrc/Abl Inhibitor -
HY-13024
RebastinibKinase Inhibitor
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 220127-57-1
-
Appearance Solid
-
Peso molecular 589.71
-
Fòrmula C30H35N7O4S
-
Color White to off-white
-
SMILES
O=S(O)(C)=O.O=C(NC1=CC=C(C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
-
Synonyms
STI571 Mesylate (Standard); CGP-57148B Mesylate (Standard)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32. [Content Brief]
[2]. Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9. [Content Brief]
[3]. Okuda K, et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8 [Content Brief]
[4]. Maj E, et al. Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model. Int J Mol Sci. 2015 Nov 13;16(11):27191-207. [Content Brief]
[5]. Tanaka S, et al. Protective Effects of Imatinib on Ischemia/Reperfusion Injury in Rat Lung. Ann Thorac Surg. 2016 Jul 23. pii: S0003-4975(16)30523-9 [Content Brief]
[6]. Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Imatinib Mesylate (Standard) Related Classifications
HY-50946R Related Classifications
Powered by Bioz